Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hamilton Anxiety Rating Scale

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: Hamilton Anxiety Rating Scale. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2006-004147-33 Sponsor Protocol Number: EFC5895 Start Date*: 2007-02-21
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An Eight-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Fixed Dose of SR58611A 350 mg Twice a Day in Elderly Patients with Generalized ...
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004960-64 Sponsor Protocol Number: F1J-MC-HMDW(b) Start Date*: 2005-05-13
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Comparison of Duloxetine Hydrochloride, Venlafaxine Extended Release, and Placebo in the Treatment of Generalized Anxiety Disorder
    Medical condition: Generalised Anxiety Disorder
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002577-23 Sponsor Protocol Number: CL2-20098-040 Start Date*: 2004-12-08
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of Agomelatine (25 mg with potential adjustment at 50 mg) given orally once a day for 12 weeks in out-patients with Generalised Anxiety Disorder. A randomised flexible dose doub...
    Medical condition: Generalised Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    3.3 10018075 P.T.
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-003181-41 Sponsor Protocol Number: EFC5893 Start Date*: 2005-08-16
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: An eight-week, double-blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy, safety and tolerability of a fixed dose of SR58611A (350...
    Medical condition: Generalized Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-000955-40 Sponsor Protocol Number: CI-1008-152 Start Date*: 2004-09-23
    Sponsor Name:Pfizer Global Research & Development
    Full Title: A Placebo-Controlled Study of Pregabalin in Elderly Patients With Generalized Anxiety Disorder
    Medical condition: Generalized Anxiety Disorder
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-003180-23 Sponsor Protocol Number: EFC5891 Start Date*: 2006-02-02
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An 8-week, double blind, placebo-controlled, multicenter study with paroxetine (20 mg q24) as positive control, evaluating the efficacy and safety of 2 fixed doses of SR58611A (175 mg q12 and 350 m...
    Medical condition: Generalized Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-001683-29 Sponsor Protocol Number: 61393215MDD2001 Start Date*: 2019-09-27
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-61393215 as Adjunctive Treatment in Adults with Major Depressive Disorder with Anxio...
    Medical condition: Adjunctive Treatment in Adults with Major Depressive Disorder with Anxious Distress with Suboptimal Response to Standard Antidepressants
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-005597-67 Sponsor Protocol Number: EFC4846 Start Date*: 2006-03-29
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A (350 mg q12) in elderly patients with Major Depressive Di...
    Medical condition: Major Depressive Disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    8.0 10018105 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004077-16 Sponsor Protocol Number: 14/0249 Start Date*: 2014-12-03
    Sponsor Name:University College London Joint Research Office
    Full Title: A Phase IV randomised controlled trial of the selective serotonin reuptake inhibitor Sertraline versus Cognitive Behavioural Therapy for anxiety symptoms in people with Generalised Anxiety Disorder...
    Medical condition: Generalised anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10037175 - Psychiatric disorders 10018075 Generalised anxiety disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002007-29 Sponsor Protocol Number: 42165279MDD2001 Start Date*: 2015-11-24
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Di...
    Medical condition: Major Depressive Disorder Anxiety
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004768-32 Sponsor Protocol Number: A0081147 Start Date*: 2008-04-21
    Sponsor Name:Pfizer S.A.
    Full Title: “ESTUDIO DE SEGURIDAD Y EFICACIA A LARGO PLAZO DE PREGABALINA EN SUJETOS CON TRASTORNO DE ANSIEDAD GENERALIZADA” "LONG TERM SAFETY AND EFFICACY STUDY OF PREGABALIN IN SUBJECTS WITH GENERALIZED ANX...
    Medical condition: Trastorno de ansiedad generalizada (TAG)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) LT (Completed) FI (Completed) AT (Completed) CZ (Completed) SI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2005-005054-46 Sponsor Protocol Number: D1448C00011 Start Date*: 2006-03-17
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR...
    Medical condition: Generalised Anxiety Disorder (GAD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) ES (Completed) DK (Completed) DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-001500-13 Sponsor Protocol Number: A0081012 Start Date*: 2005-01-24
    Sponsor Name:Pfizer Ltd.
    Full Title: An 8-week, multicentre, randomised, double-blind, placebo-controlled, flexible dose study of Pregabalin (300-600 mg/day) and Venlafaxine XR (75-225 mg/day) for the acute treatment of DSM-IV General...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    7.0 10018105 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002253-71 Sponsor Protocol Number: LTE5894 Start Date*: 2006-10-04
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Estudio doble ciego, multicéntrico y aleatorizado de retirada de pacientes, que evalúa la eficacia y seguridad de Amibegron (350 mg dos veces al día) frente a placebo en la prevención de recaídas ...
    Medical condition: trastorno de ansiedad generalizada.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) HU (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-001766-90 Sponsor Protocol Number: LuAA21004_311 Start Date*: 2009-04-09
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxie...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018075 Generalised anxiety disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed) LV (Completed) EE (Completed) LT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-000438-21 Sponsor Protocol Number: 750201.01.035 Start Date*: 2012-10-17
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-center, double-blind, placebo-controlled, randomized phase III study to prove the efficacy, safety and tolerability of Silexan (WS®1265) in patients with mixed anxiety and depressive disorder...
    Medical condition: mixed anxiety and depressive disorder (ICD-10, F41.2)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10027741 Mixed anxiety & depressive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013789-17 Sponsor Protocol Number: CL3-20098-071 Start Date*: 2010-03-11
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment to 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou...
    Medical condition: Generalized anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004937-15 Sponsor Protocol Number: BNC210.006 Start Date*: 2015-04-16
    Sponsor Name:BIONOMICS LIMITED
    Full Title: A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured...
    Medical condition: Generalized Anxiety Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10018105 Generalized anxiety disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001325-27 Sponsor Protocol Number: 18314A Start Date*: 2019-12-26
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, open-label effectiveness study of flexible doses of vortioxetine on depressive symptoms in patients with major depressive disorder comorbid with generalized anxiety disorder
    Medical condition: Depressive symptoms in patients with major depressive disorder (MDD) comorbid with generalized anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006121-26 Sponsor Protocol Number: 40411813DAX2001 Start Date*: 2012-06-06
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled Study of JNJ-40411813 as Adjunctive Treatment to an Antidepressant in Adults with Major Depressive Disorder with Anxiety Symptoms
    Medical condition: Major Depressive Disorder with Anxiety Symptoms
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:37:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA